硼替佐米降低IgA肾病蛋白尿的初步试验
该初步试验纳入8例活检证实的IgA肾病且蛋白尿>1g/天的患者,给予4剂硼替佐米(1.3mg/m2体表面积,静脉注射),随访1年。主要终点为完全缓解(蛋白尿<300mg/天)。结果显示3例(38%)达到主要终点,这3例基线Oxford分类T评分均为0且肾功能正常;其余4例(50%)无应答或疾病进展,1例失访。提示硼替佐米可能对选择性IgA肾病病例减少蛋白尿。
要点
- 硼替佐米可能减少选择性IgA肾病患者的显著蛋白尿。
- 达到完全缓解者基线Oxford分类T评分均为0且肾功能正常。
- 4例(50%)无应答或疾病进展,1例失访。
核心结论
- 硼替佐米通过蛋白酶体抑制可能减少选择性IgA肾病病例的显著蛋白尿。
- 对硼替佐米有应答的受试者具有Oxford分类T评分0和正常肾功能。
研究设计与样本
- 初步试验(NCT01103778),2011年7月至2016年3月连续治疗8例活检证实的IgA肾病且蛋白尿>1g/天的受试者。
- 给予4剂硼替佐米静脉注射,每剂1.3mg/m2体表面积,2周内完成;随访1年。
- 主要终点为完全缓解,定义为蛋白尿<300mg/天。
主要发现
- 8例受试者均耐受并完成4剂硼替佐米治疗。
- 基线中位每日蛋白尿为2.46g(四分位距:2.29-3.16g)。
- 1年随访时,3例(38%)达到主要终点。
- 达到完全缓解的3例基线Oxford分类T评分均为0。
- 其余5例中,1例在入组1个月内失访,4例(50%)无应答或疾病进展。
关键数值与推荐
- 完全缓解定义为蛋白尿<300mg/天。
- 入组标准为活检证实的IgA肾病且蛋白尿>1g/天。
- 硼替佐米剂量为1.3mg/m2体表面积,静脉注射,共4剂。
临床怎么用
- 硼替佐米可能作为选择性IgA肾病伴显著蛋白尿患者的潜在治疗选择,尤其对Oxford分类T评分0且肾功能正常者。
- 治疗前应评估Oxford分类T评分和肾功能以识别可能应答者。
局限性
- 样本量小(8例),为初步试验。
- 1例失访,可能影响结果解读。
- 缺乏对照组,无法排除自然病程或其他因素影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: IgA nephropathy is the most common glomerulonephritis in the world. We conducted a pilot trial (NCT01103778) to test the effect of bortezomib in patients with IgA nephropathy and significant proteinuria. METHODS: We treated 8 consecutive subjects from July 2011 until March 2016 with 4 doses of bortezomib. All subjects had biopsy-proven IgA nephropathy and proteinuria of greater than 1 g per day. They were given 4 doses of bortezomib i.v. at 1.3 mg/m2 of body surface area per dose. Changes in proteinuria and renal function were followed for 1 year after enrollment. The primary endpoint was full remission defined as proteinuria of less than 300 mg per day. RESULTS: All 8 subjects received and tolerated 4 doses of bortezomib over a 2-week period during enrollment. The median baseline daily proteinuria was 2.46 g (interquartile range: 2.29-3.16 g). At 1-year follow-up, 3 subjects (38%) had achieved the primary endpoint. The 3 subjects who had complete remission had Oxford classification T scores of 0 before enrollment. Of the remaining 5 subjects, 1 was lost to follow-up within 1 month of enrollment and 4 (50%) did not have any response or had progression of disease. CONCLUSION: Proteasome inhibition by bortezomib may reduce significant proteinuria in select cases of IgA nephropathy. Subjects who responded to bortezomib had Oxford classification T score of 0 and normal renal function.
引用
- Hartono C, Chung M, Perlman AS, et al. Bortezomib for Reduction of Proteinuria in IgA Nephropathy. Kidney Int Rep. 2018. PMID: 29988921. doi:10.1016/j.ekir.2018.03.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。